Canada: Canadian Drug Patent Enforcement

Last Updated: September 11 2017
Article by Noel Courage

Canadian patents have recently received a boost from the federal government and courts. Our top court recently removed the promise doctrine from patent utility law as a basis to challenge patents. New laws are going to beef up linkage regulations and create patent term extensions for drugs. Patent and design registrations are also being streamlined.

Promise doctrine eliminated as a ground of patent invalidity

The "promise doctrine" in the Canadian patent law of utility received a lot of press in the pharma industry. As the doctrine caught hold the past decade or so, Canadian utility became out of line with the law in the US and UK, where the utility standard is easily met. Under the promise doctrine, if any promises of utility in the patent specification were not met, then potentially the entire patent could be held invalid. This was an alarming proposition considering that brand name drug companies often make bold predictions that compounds will have a wide range of utilities to treat multiple diseases. Promise doctrine was primarily an issue in pharma patent cases, but Canadian utility had been used as a successful basis to invalidate claims in a mechanical patent case involving helicopter landing gear. There was no up-side for patent owners in the proliferation of the promise doctrine, and many were vexed by having to defend against promise doctrine. Eli Lilly went so far as to launch a failed North American Free Trade Agreement ("NAFTA") complaint against the Canadian government over Canadian utility after patents for the drugs atomoxetine and olanzapine were invalidated. A recent survey sponsored by the brand name pharma association in Canada, for what it's worth, alleged that the weakening patent environment in Canada was hitting Canadian R&D spending in the pocketbook.

Generic drug companies began to try to elevate every statement of advantage in a patent to a promise. Brand name companies downplayed their apparent promises. The case law on promise doctrine became conflicted, so Canadian patent attorneys scratched their heads as to the applicability and scope of the doctrine. Promise doctrine became a standard ground of attack for generic drug companies challenging patents. They won some cases and lost others, so it was certainly not open season on pharma patents in Canada. Examples of cases where brandname drug company patents were found valid in spite of generic challenges based on promise doctrine include cases for clopidogrel sulfate1 (the blockbuster drug Plavix) and celcoxib2 (the blockbuster drug Celebrex). However, the uncertainty around promise doctrine needed to be resolved.

The promise doctrine ended up on the table at the Supreme Court of Canada3, and the judgment was released in July 2017. There were two alleged promises made in the patent. One of the main issues was whether both promises had to be fully met in order for the patent to be valid. Note that the first promise, shown below, is about a chemical reaction (inhibiting proton/acid in the stomach), which is easy to demonstrate though a lab benchtop experiment. The second promise is more complex and harder to prove, that the drug works more effectively for a wider range of persons.

The Court identified the promises as follows: [9] ... two promises of utility in the '653 patent: (1) use as a proton pump inhibitor; and (2) improved pharmacokinetic and metabolic properties which would give an improved therapeutic profile such as a lower degree of interindividual variation. In other words, the drug would (1) reduce the amount of acid in the stomach; and (2) work more effectively for a wider range of persons, having less variation in patient response.

The Supreme Court decided that it was enough for the patent to disclose something useful – all promises did not have to be kept. The patent was valid and enforceable. Once the first promise was met, the court did not have to look at second promise. This directly overturned the lower court which had decided that all promises must be met, and the second promise was not met in the patent, so it was invalid.

The Supreme Court called the promise doctrine "unsound", so it is now effectively dead. The bar for utility set by the Court is now that, "The invention must be capable of an actual relevant use and not be devoid of utility."A mere scintilla of utility will suffice.

This case provided clarity by snuffing out the promise doctrine and bringing Canada back more towards the lower standard in US and UK utility law. We have a lot more certainty now that technical legal attacks on the utility of a patent generally cannot invalidate the patent. This is a sensible result, since, in the real world, the patent covers a drug that is clearly very useful and valuable, or else a generic company would not be trying to copy it.

Drug linkage regulations being strengthened

The patent environment for innovative drug companies in Canada has the benefit of linkage regulations. These rules link generic drug regulatory approval to the precondition of first clearing certain brand name drug patent issues. The US has linkage regulations (Orange Book, ANDA proceedings etc), but the EU does not have such regulations. One can easily judge the importance of these linkage regulations to Canadian brand named pharma merely by how they have made the generic industry association apoplectic for over two decades. The newly-released revised draft linkage regulations are going to make them into an "action", determinative of patent infringement and validity issues, similar to the US ANDA Proceedings (currently, the Canadian linkage regulations are an "application", an affidavit-based process, that considers infringement and validity issues, but is not determinative)4.

The revised system will have the benefit for both brand name and generic companies of reducing the multiplicity of litigation under the current system. Linkage proceedings will no longer be followed by patent infringement or impeachment actions, since they will now incorporate the actions. Early and active case management will be necessary to resolve these cases within the required 24 months.

Patent term extension

The Canadian government also just introduced draft regulations to implement up to two years of patent term extension5. This will be made available by way of a Supplementary Protection Certificate ("SPC"), only in the event that there is regulatory delay by Health Canada in review of a drug submission. The proposed Canadian SPC system is generally based on the European SPC system. It provides the same practical effect as a patent term extension, but the additional patent protection is effected by the SPC. The SPC is limited to the particular medicine that is an approved drug. For example, if the patent covers non-commercialized drugs, the non-commercialized drugs will not be protected further. The patent will have to pertain to a medicinal ingredient, or a combination, that was authorized after a cut-off date to be set by government. Drugs approved for sale in Canada prior to this cut-off date will not be eligible to apply for an SPC (i.e. currently-approved drugs will not be grandfathered into the SPC system). This improved patent protection term reinforces that it's still a good environment in Canada to do research and development and file patent applications.

Other changes in patent and design law

There are draft Patent Rules6 and Design Rules7 coming into force in the near future, which will bring the Patent Law Treaty and the Hague Agreement (industrial designs) into effect. The Patent Law Treaty amendments will streamline and harmonize certain Canadian filing formalities. The new rules will also have significant effects, such as on abandonment/reinstatement rights and introducing restoration of priority. The one-year grace period for late national phase entry as-of-right will continue to exist (ie. Up to 42 months from priority date), but will be significantly curtailed, requiring that the 30 month deadline was missed unintentionally. There will be three years to request examination (down from five months) and 4 months to respond to Office Actions (down from six months).

The Hague Agreement is an international industrial design filing system already implemented in the US and many other major countries. It allows filing of a single design application as a basis to protect design rights internationally. A major change coming to the Canadian design law is that the term will change from 10 years from issuance to 15 years from the application filing date. Novelty requirements are also being changed.

Overall, the net effect of the amendments is positive. The changes streamline many aspects of Canadian patenting, and certain types of patent and design rights are strengthened. This allows faster and more cost-effective IP registrations.

Footnotes

1 Sanofi-Aventis v. Apotex Inc., 2013 FCA 186.

2 Apotex Inc. v. Pfizer Canada Inc., 2014 FCA 250.

3 AstraZeneca Canada Inc. v. Apotex Inc., 2015 FCA 158.

4 Regulations Amending the Patented Medicines (Notice of Compliance) Regulations, 2017. Canada Gazette. Vol. 151, No. 28. July 15, 2017. http://www.canadagazette.gc.ca/rp-pr/p1/2017/2017-07-15/html/ Regulations Amending the Patented Medicines (Notice of Compliance) Regulations, 2017. Canada Gazette. Vol. 151, No. 28. July 15, 2017. http://www.canadagazette.gc.ca/rp-pr/p1/2017/2017-07-15/html/ reg18-eng.php

5 Certificate of Supplementary Protection Regulations. Canada Gazette. Vol. 151, No. 28 — July 15, 2017. http://www.canadagazette.gc.ca/ rp-pr/p1/2017/2017-07-15/html/Certificate of Supplementary Protection Regulations. Canada Gazette. Vol. 151, No. 28 — July 15, 2017. http://www.canadagazette.gc.ca/ rp-pr/p1/2017/2017-07-15/html/reg16-eng.php

6 Proposed Patent Rules draft. http://www.ic.gc.ca/eic/site/cipointernetinternetopic. nsf/eng/Proposed Patent Rules draft. http://www.ic.gc.ca/eic/site/cipointernetinternetopic. nsf/eng/wr04281.html

7 Proposed Industrial Design Regulations draft. https://www.ic.gc.ca/eic/site/cipointernet-internetopic.nsf/eng/wr04255.html

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

To print this article, all you need is to be registered on Mondaq.com.

Click to Login as an existing user or Register so you can print this article.

Authors
 
In association with
Related Topics
 
Related Articles
 
Related Video
Up-coming Events Search
Tools
Print
Font Size:
Translation
Channels
Mondaq on Twitter
 
Register for Access and our Free Biweekly Alert for
This service is completely free. Access 250,000 archived articles from 100+ countries and get a personalised email twice a week covering developments (and yes, our lawyers like to think you’ve read our Disclaimer).
 
Email Address
Company Name
Password
Confirm Password
Position
Mondaq Topics -- Select your Interests
 Accounting
 Anti-trust
 Commercial
 Compliance
 Consumer
 Criminal
 Employment
 Energy
 Environment
 Family
 Finance
 Government
 Healthcare
 Immigration
 Insolvency
 Insurance
 International
 IP
 Law Performance
 Law Practice
 Litigation
 Media & IT
 Privacy
 Real Estate
 Strategy
 Tax
 Technology
 Transport
 Wealth Mgt
Regions
Africa
Asia
Asia Pacific
Australasia
Canada
Caribbean
Europe
European Union
Latin America
Middle East
U.K.
United States
Worldwide Updates
Registration (you must scroll down to set your data preferences)

Mondaq Ltd requires you to register and provide information that personally identifies you, including your content preferences, for three primary purposes (full details of Mondaq’s use of your personal data can be found in our Privacy and Cookies Notice):

  • To allow you to personalize the Mondaq websites you are visiting to show content ("Content") relevant to your interests.
  • To enable features such as password reminder, news alerts, email a colleague, and linking from Mondaq (and its affiliate sites) to your website.
  • To produce demographic feedback for our content providers ("Contributors") who contribute Content for free for your use.

Mondaq hopes that our registered users will support us in maintaining our free to view business model by consenting to our use of your personal data as described below.

Mondaq has a "free to view" business model. Our services are paid for by Contributors in exchange for Mondaq providing them with access to information about who accesses their content. Once personal data is transferred to our Contributors they become a data controller of this personal data. They use it to measure the response that their articles are receiving, as a form of market research. They may also use it to provide Mondaq users with information about their products and services.

Details of each Contributor to which your personal data will be transferred is clearly stated within the Content that you access. For full details of how this Contributor will use your personal data, you should review the Contributor’s own Privacy Notice.

Please indicate your preference below:

Yes, I am happy to support Mondaq in maintaining its free to view business model by agreeing to allow Mondaq to share my personal data with Contributors whose Content I access
No, I do not want Mondaq to share my personal data with Contributors

Also please let us know whether you are happy to receive communications promoting products and services offered by Mondaq:

Yes, I am happy to received promotional communications from Mondaq
No, please do not send me promotional communications from Mondaq
Terms & Conditions

Mondaq.com (the Website) is owned and managed by Mondaq Ltd (Mondaq). Mondaq grants you a non-exclusive, revocable licence to access the Website and associated services, such as the Mondaq News Alerts (Services), subject to and in consideration of your compliance with the following terms and conditions of use (Terms). Your use of the Website and/or Services constitutes your agreement to the Terms. Mondaq may terminate your use of the Website and Services if you are in breach of these Terms or if Mondaq decides to terminate the licence granted hereunder for any reason whatsoever.

Use of www.mondaq.com

To Use Mondaq.com you must be: eighteen (18) years old or over; legally capable of entering into binding contracts; and not in any way prohibited by the applicable law to enter into these Terms in the jurisdiction which you are currently located.

You may use the Website as an unregistered user, however, you are required to register as a user if you wish to read the full text of the Content or to receive the Services.

You may not modify, publish, transmit, transfer or sell, reproduce, create derivative works from, distribute, perform, link, display, or in any way exploit any of the Content, in whole or in part, except as expressly permitted in these Terms or with the prior written consent of Mondaq. You may not use electronic or other means to extract details or information from the Content. Nor shall you extract information about users or Contributors in order to offer them any services or products.

In your use of the Website and/or Services you shall: comply with all applicable laws, regulations, directives and legislations which apply to your Use of the Website and/or Services in whatever country you are physically located including without limitation any and all consumer law, export control laws and regulations; provide to us true, correct and accurate information and promptly inform us in the event that any information that you have provided to us changes or becomes inaccurate; notify Mondaq immediately of any circumstances where you have reason to believe that any Intellectual Property Rights or any other rights of any third party may have been infringed; co-operate with reasonable security or other checks or requests for information made by Mondaq from time to time; and at all times be fully liable for the breach of any of these Terms by a third party using your login details to access the Website and/or Services

however, you shall not: do anything likely to impair, interfere with or damage or cause harm or distress to any persons, or the network; do anything that will infringe any Intellectual Property Rights or other rights of Mondaq or any third party; or use the Website, Services and/or Content otherwise than in accordance with these Terms; use any trade marks or service marks of Mondaq or the Contributors, or do anything which may be seen to take unfair advantage of the reputation and goodwill of Mondaq or the Contributors, or the Website, Services and/or Content.

Mondaq reserves the right, in its sole discretion, to take any action that it deems necessary and appropriate in the event it considers that there is a breach or threatened breach of the Terms.

Mondaq’s Rights and Obligations

Unless otherwise expressly set out to the contrary, nothing in these Terms shall serve to transfer from Mondaq to you, any Intellectual Property Rights owned by and/or licensed to Mondaq and all rights, title and interest in and to such Intellectual Property Rights will remain exclusively with Mondaq and/or its licensors.

Mondaq shall use its reasonable endeavours to make the Website and Services available to you at all times, but we cannot guarantee an uninterrupted and fault free service.

Mondaq reserves the right to make changes to the services and/or the Website or part thereof, from time to time, and we may add, remove, modify and/or vary any elements of features and functionalities of the Website or the services.

Mondaq also reserves the right from time to time to monitor your Use of the Website and/or services.

Disclaimer

The Content is general information only. It is not intended to constitute legal advice or seek to be the complete and comprehensive statement of the law, nor is it intended to address your specific requirements or provide advice on which reliance should be placed. Mondaq and/or its Contributors and other suppliers make no representations about the suitability of the information contained in the Content for any purpose. All Content provided "as is" without warranty of any kind. Mondaq and/or its Contributors and other suppliers hereby exclude and disclaim all representations, warranties or guarantees with regard to the Content, including all implied warranties and conditions of merchantability, fitness for a particular purpose, title and non-infringement. To the maximum extent permitted by law, Mondaq expressly excludes all representations, warranties, obligations, and liabilities arising out of or in connection with all Content. In no event shall Mondaq and/or its respective suppliers be liable for any special, indirect or consequential damages or any damages whatsoever resulting from loss of use, data or profits, whether in an action of contract, negligence or other tortious action, arising out of or in connection with the use of the Content or performance of Mondaq’s Services.

General

Mondaq may alter or amend these Terms by amending them on the Website. By continuing to Use the Services and/or the Website after such amendment, you will be deemed to have accepted any amendment to these Terms.

These Terms shall be governed by and construed in accordance with the laws of England and Wales and you irrevocably submit to the exclusive jurisdiction of the courts of England and Wales to settle any dispute which may arise out of or in connection with these Terms. If you live outside the United Kingdom, English law shall apply only to the extent that English law shall not deprive you of any legal protection accorded in accordance with the law of the place where you are habitually resident ("Local Law"). In the event English law deprives you of any legal protection which is accorded to you under Local Law, then these terms shall be governed by Local Law and any dispute or claim arising out of or in connection with these Terms shall be subject to the non-exclusive jurisdiction of the courts where you are habitually resident.

You may print and keep a copy of these Terms, which form the entire agreement between you and Mondaq and supersede any other communications or advertising in respect of the Service and/or the Website.

No delay in exercising or non-exercise by you and/or Mondaq of any of its rights under or in connection with these Terms shall operate as a waiver or release of each of your or Mondaq’s right. Rather, any such waiver or release must be specifically granted in writing signed by the party granting it.

If any part of these Terms is held unenforceable, that part shall be enforced to the maximum extent permissible so as to give effect to the intent of the parties, and the Terms shall continue in full force and effect.

Mondaq shall not incur any liability to you on account of any loss or damage resulting from any delay or failure to perform all or any part of these Terms if such delay or failure is caused, in whole or in part, by events, occurrences, or causes beyond the control of Mondaq. Such events, occurrences or causes will include, without limitation, acts of God, strikes, lockouts, server and network failure, riots, acts of war, earthquakes, fire and explosions.

By clicking Register you state you have read and agree to our Terms and Conditions